Stocks making the biggest moves after hours: Adobe, RH, Oracle and more

Stock Market

External view of the stand where Adobe Digital Imaging Evangelist Director, Photoshop & Lightroom Julieanne Kost conduct a Lightroom workshop at Xposure on February 29, 2024, in Sharjah, United Arab Emirates.
Horacio Villalobos | Corbis News | Getty Images

Check out the companies making headlines in extended trading:

Adobe — Shares plunged more than 10% after the software company issued soft guidance. Adobe issued a fiscal fourth-quarter revenue forecast in a range between $5.50 billion and $5.55 billion. Analysts polled by LSEG had estimated $5.61 billion in revenue. Guidance for adjusted earnings per share came in at $4.63 to $4.68 per share, while analysts had expected $4.67 in earnings per share. Meanwhile, third-quarter adjusted earnings and revenue beat estimates. 

Oracle — The cloud software company advanced nearly 6% after raising its revenue guidance. The company announced during its analyst day on Thursday that it estimates 2026 revenue of at least $66 billion, higher than prior guidance for $65 billion and analysts’ forecast for $64.8 billion, per FactSet. 

Neurocrine Biosciences — The neuroscience-focused biopharma company lost more than 2%. Neurocrine Biosciences reported that its investigational drug luvadaxistat, a schizophrenia treatment, failed to reach primary endpoints in a phase two study. 

RH — The home furnishings company surged nearly 19% after posting a top- and bottom-line beat for the fiscal second quarter. RH reported adjusted earnings of $1.69 per share on $830 million in revenue. Analysts surveyed by LSEG had called for $1.56 in earnings per share and revenue of $825 million. 

Aptiv PLC — Shares of the auto parts company added 1.7%. A filing with the U.S. Securities and Exchange Commission showed CEO Kevin Clark purchased nearly 30,000 shares earlier this week. 

CNBC’s Nick Wells contributed reporting.

Articles You May Like

UK house sales rise since the Covid-19 boom as lower mortgage rates spur activity
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
Dennis Enright, founding principal at NW Financial, dies
In a heavy new-issue market, specialty states, HY see oversubscriptions
Top Wall Street analysts favor these stocks for attractive long-term potential